文献速递胸部肿瘤

局限期小细胞肺癌联合放化疗应用的障碍

Barriers to Combined-Modality Therapy for Limited-Stage Small Cell Lung Cancer.
PubMed 文献 · JAMA Oncol · 2018-08-09

该研究基于美国国家癌症数据库分析2004至2013年全部局限期小细胞肺癌(SCLC)病例的初始治疗。结果显示,仅55.5%接受化疗联合放疗,20.5%仅化疗,3.5%仅放疗,20.0%两者均未接受;无保险与政府保险覆盖与治疗利用降低及生存缩短相关。

要点

  • 局限期SCLC中仅55.5%接受化疗联合放疗,20.0%两者均未接受。
  • 无保险者接受化疗和放疗的可能性均更低。
  • 化疗(HR 0.55)和放疗(HR 0.62)均与生存获益相关。

核心结论

  • 相当比例的局限期SCLC患者初始治疗未接受放疗或化疗,且与较差生存相关。
  • 放疗未实施独特地与政府保险覆盖相关,提示需针对性改善该人群的可及性。

研究设计与样本

  • 基于美国国家癌症数据库的回顾性分析,纳入2004至2013年全部局限期SCLC病例的初始管理。
  • 共70 247例符合纳入标准,55.3%为女性,中位年龄68岁(范围19-90岁)。

主要发现

  • 初始治疗为化疗联合放疗者占55.5%,仅化疗20.5%,仅放疗3.5%,两者均无20.0%(未报告0.5%)。
  • 四组中位生存分别为18.2个月(95%CI 17.9-18.4)、10.5个月(95%CI 10.3-10.7)、8.3个月(95%CI 7.7-8.8)和3.7个月(95%CI 3.5-3.8)。
  • 多因素分析中,无保险与接受化疗(OR 0.65;95%CI 0.56-0.75;P<.001)和放疗(OR 0.75;95%CI 0.67-0.85;P<.001)的可能性降低相关。
  • Medicaid(OR 0.79;95%CI 0.72-0.87;P<.001)和Medicare(OR 0.86;95%CI 0.82-0.91;P<.001)与放疗实施可能性降低独立相关,Medicare/Medicaid对化疗使用无影响。
  • 调整分析中,无保险(HR 1.19;95%CI 1.13-1.26;P<.001)、Medicaid(HR 1.27;95%CI 1.21-1.32;P<.001)和Medicare(HR 1.12;95%CI 1.09-1.15;P<.001)与生存缩短独立相关,化疗(HR 0.55;95%CI 0.54-0.57;P<.001)和放疗(HR 0.62;95%CI 0.60-0.63;P<.001)与生存获益相关。

临床怎么用

  • 对局限期SCLC应评估化疗与放疗的联合实施情况,关注未接受任一治疗的患者。
  • 对无保险及Medicaid/Medicare覆盖患者,需关注放疗可及性并针对性改善。
  • 保险状态与生存相关,提示在治疗决策中评估社会经济障碍。

局限性

  • 为回顾性数据库分析,作者指出需进一步工作才能确证确切人群模式、具体治疗缺陷及导致治疗异质性的原因。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Combined-modality therapy with chemotherapy and radiation therapy plays a crucial role in the upfront treatment of patients with limited-stage small cell lung cancer (SCLC), but there may be barriers to utilization in the United States. OBJECTIVE: To estimate utilization rates and factors associated with chemotherapy and radiation therapy delivery for limited-stage SCLC using the National Cancer Database. DESIGN, SETTING, AND PARTICIPANTS: Analysis of initial management of all limited-stage SCLC cases from 2004 through 2013 in the National Cancer Database. MAIN OUTCOMES AND MEASURES: Utilization rates of chemotherapy and radiation therapy at time of initial treatment. Multivariable analysis identified independent clinical and socioeconomic factors associated with utilization and overall survival. RESULTS: A total of 70 247 cases met inclusion criteria (55.3% female; median age, 68 y [range, 19-90 y]). Initial treatment was 55.5% chemotherapy and radiation therapy, 20.5% chemotherapy alone, 3.5% radiation therapy alone, and 20.0% neither (0.5% not reported). Median survival was 18.2 (95% CI, 17.9-18.4), 10.5 (95% CI, 10.3-10.7), 8.3 (95% CI, 7.7-8.8), and 3.7 (95% CI, 3.5-3.8) months, respectively. Being uninsured was associated with a lower likelihood of both chemotherapy (odds ratio [OR], 0.65; 95% CI, 0.56-0.75; P < .001) and radiation therapy (OR, 0.75; 95% CI, 0.67-0.85; P < .001) administration on multivariable analysis. Medicare/Medicaid insurance had no impact on chemotherapy use, whereas Medicaid (OR, 0.79; 95% CI, 0.72-0.87; P < .001) and Medicare (OR, 0.86; 95% CI, 0.82-0.91; P < .001) were independently associated with a lower likelihood of radiation therapy delivery. Lack of health insurance (HR, 1.19; 95% CI, 1.13-1.26; P < .001), Medicaid (HR, 1.27; 95% CI, 1.21-1.32; P < .001), and Medicare (HR, 1.12; 95% CI, 1.09-1.15; P < .001) coverage were independently associated with shorter survival on adjusted analysis, while chemotherapy (HR, 0.55; 95% CI, 0.54-0.57; P < .001) and radiation therapy (HR, 0.62; 95% CI, 0.60-0.63; P < .001) were associated with a survival benefit. CONCLUSIONS AND RELEVANCE: Substantial proportions of patients documented in a major US cancer registry did not receive radiation therapy or chemotherapy as part of initial treatment for limited-stage SCLC, which, in turn, was associated with poor survival. Lack of radiation therapy delivery was uniquely associated with government insurance coverage, suggesting a need for targeted access improvement in this population. Additional work will be necessary to conclusively define exact population patterns, specific treatment deficiencies, and causative factors leading to heterogeneous care delivery.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Pezzi TA, Schwartz DL, Mohamed ASR, et al. Barriers to Combined-Modality Therapy for Limited-Stage Small Cell Lung Cancer. JAMA Oncol. 2018. PMID: 29302695. doi:10.1001/jamaoncol.2017.4504

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。